Background Ghrelin is a peptide hormone with pleiotropic effects. It stimulates cell proliferation and inhibits apoptosis-mediated cell death. It prevents diabetes mellitus in several models of chemical, surgical and biological toxic insults to pancreas in both in vivo and in vitro models and promotes glucose-stimulated insulin secretion under cytotoxic conditions. It has not yet been tested in vivo in an autoimmune model of diabetes with a persistent insult to the β-cell. Given the immunomodulating effects of ghrelin and its trophic effects on β-cells, we hypothesized that ghrelin treatment during the early stages of insulitis would delay diabetes onset.
Introduction
Ghrelin is a peptide hormone consisting of a chain of 28 amino acids. It was first described in 1999 as the natural ligand of the orphan growth hormone secretagogue receptor [1] and was initially known to promote growth hormone (GH) secretion stimulating directly the somatotrophs at the pituitary and indirectly by antagonizing somatostatin [2] . It is also the first peripheral peptide known to induce hunger, stimulating neuropeptide Y production at the hypothalamus [3] . The primary regulatory mechanism for ghrelin secretion is related to this function: its production and secretion is enhanced during fasting and peaks just before food intake [4] that in turn, induces a down-regulation in its circulating levels [5] . Besides these systemic effects, at the cellular level, ghrelin promotes cell survival, differentiation and proliferation in multiple cell types, including cell lines, primary cultures and in vivo grafts after transplant (for review see [6] ).
In the early stages of type 1 diabetes mellitus (T1D), patients suffer an autoimmune-driven loss of insulin-producing β-cells' mass and function. The Langerhans islets are assaulted by an immune infiltrate that disrupts β-cell functionality and turnover rate, eventually causing cellular death and islet insufficiency, leading to hyperglycaemia and diabetes.
Ghrelin in both of its circulating forms (acyl and desacylghrelin) has been shown to stimulate proliferation of and to promote survival of β-cells in several pathologic models: it mitigates β-cell destruction induced by different toxins, both in vitro [7] [8] [9] and in vivo [10, 11] ; it increases functional β-cell mass after extensive pancreatectomy in rodents [12] ; and it has recently been demonstrated that ghrelin promotes insulin secretion in response to glucose in a cytotoxic environment in vitro [13] . Both of its circulating forms (as well as obestatin -another product of the ghrelin gene by alternative splicing) boost β-cell regeneration after administration of streptozotocin (a compound which specifically induces β-cell destruction [14] ) in newborn rats protecting against diabetes in adult life [15] [16] [17] , and obestatin reduces the damage to the pancreas caused by ischemia/reperfusion [18] . Ghrelin also inhibits human lymphocyte and monocyte pro-inflammatory cytokine production [19, 20] , and obestatin decreases leukocyte infiltration in acute pancreatitis [18] , in addition to other immunomodulatory effects at various levels (for review see [21] ). Hence, we hypothesized that ghrelin treatment during early stages of insulitis would prevent β-cell mass loss and ultimately delay diabetes onset.
We used BioBreeding/Worcester rats (BB rats) that spontaneously develop an autoimmune infiltrate against β-cells leading to an absolute insulin deficiency similar to human T1D. This Wistar-derived colony, generated in 1974 at Bio-Breeding Laboratories (Ottawa, Canada), is not obese, and the disease occurs equally in both sexes. The cumulative incidence of diabetes and the age of diabetes onset in these animals may vary between colonies [22] . In our colony, diabetes becomes symptomatic at a mean age of 69.6 days of age, and the cumulative incidence over 90 days of age is 95%. As in human T1D, BB rats' diabetes onset is preceded by an insulitis period characterized by a monolymphocytic infiltration of islets [23, 24] and, subsequently, a more evident infiltration formed by CD4
+ T cells (T Helper cells), CD8
+ T cells (cytotoxic T cells) and B lymphocytes. Pro-inflammatory cytokines secreted by infiltrating cells can be detected in pancreatic tissue from the first stages of lymphocytic infiltration [25, 26] , and β-cell death by apoptosis has been observed before the clinical onset of diabetes [27] . Because of its autoimmune origin, immunosuppression therapies such as thymectomy early after lactation have been reported to be effective in generating diabetes-free BB rats [28] . We have previously described a reduction in β-cell proliferation preceding apoptosis and changes in islet morphometry at early stages of preclinical diabetes in these animals [29] . Here, we describe the effects of ghrelin treatment on insulitis, β-cell mass and diabetes onset. BioBreeding/Worcester male rats were kept under conventional conditions in an environment-controlled room (20-21°C, 12-h light-dark cycle), with water and standard laboratory rat chow available ad libitum. For the food intake control, animals were caged individually for 2 weeks in metabolic cages, allowing for water and food intake as well as diuresis daily quantification. Random weekly glucose measurements were obtained from tail vein puncture using an automatic glucose monitor (Accucheck Optimun, Roche Diagnostic, Basel, Switzerland).
Materials and methods

Animals and treatments
For the glucose and insulin tolerance tests, all histological analyses and hormonal determinations, we used a set of three groups of animals: ghrelin-treated BB rats, receiving daily subcutaneous injections of acylated ghrelin (10 ng/ kg/day) (Bachem, Bubendorf, Switzerland), and two other groups, both receiving daily injections of vehicle (sterile water), age-matched intact BB rats and thymectomized BB rats, as our control group. Injections were started at 4 weeks of age and administered daily from 08:30 to 09:30 h.
Rats (n ≥ 4 per group) were killed in a CO 2 chamber at 5, 7, 9 and 10 weeks of age, 24 h after performing functional tests. Animals presenting diabetes clinical onset (polyuria, weight loss and random glucose > 300 mg/dL) were excluded from functional and morphometric studies.
A second set of animals was used for the survival curve. Only two groups were included for this analysis, both intact BB rats, receiving either ghrelin (n = 36) or vehicle (n = 32), at the samedosesandfromthesametimeastheformersetofanimals. On the first day, animals presented a random glucose >300 mg/dL; they would be recorded as an event on the survival curve and were sacrificed immediately, in a CO 2 chamber.
Glucose tolerance test
To evaluate alterations in glucose homeostasis in vivo, we performed glucose tolerance test. Rats were fasted for 16 h and injected intraperitoneally with glucose at 2 g/kg body weight. Bloodsampleswereextractedfromtailveins,andglucoselevels were determined with an automatic glucose monitor (Accucheck Optimun) and plotted as a function of time. The area under the curve (AUC) was calculated using an equation that quantifies the incremental area above the baseline, where only the area above the fasting level for each rat is taken into account. Samples for insulin determination were collected at 0 and 15 min time points using capillary tubes precoated with potassium-EDTA (Microvette ® , Sarstedt, Nümbrecht, Germany). Plasma insulin levels were measured using ultrasensitive rat enzyme-linked immunosorbent assay (ALPCO Diagnostics, Salem, NH, USA). Intraperitoneal glucose tolerance test (IPGTT) was not performed in any animal after diabetes onset.
Insulin tolerance test
To analyse alterations in insulin sensitivity in vivo, we performed an insulin tolerance test. After a 16-h fast, rats received 0.75 IU/kg of human recombinant insulin (Humulin R; from Eli Lilly, Indianapolis, IN, USA) subcutaneously. Blood samples were collected at 0, 30, 60, 120 and 180 min from the tail, and glucose levels were determined with an automatic glucose monitor (Accucheck Optimun) and plotted as a function of time.
β-cell mass histomorphometry
At sacrifice, pancreata were removed, cleaned of visible fat, weighed and fixed in Bouin's solution (Sigma-Aldrich, St. Louis, MO, USA) for 4 h. Fixed tissues were extensively washed in water and immersed in neutral buffer formalin for 2 days. Tissues were then dehydrated and paraffin embedded. Two standard paraffin sections of 5 μm per pancreas were labelled using a monoclonal mouse anti-insulin antibody (1 : 1000), (Sigma-Aldrich, St Louis, MO, USA) and counterstained with haematoxylin. Histomorphometry was performed using the IMAGEJ software (NIH, Bethesda, MD, USA), collecting the β-cell area and number of islets as well as the total pancreatic area. β-cell mass was obtained in milligrams applying the following formula: (total β-cell area/total pancreatic area) · pancreas weight.
Histological examination of insulitis
Histological examination of pancreatic islets was performed in two fixed pancreas sections per animal stained with Harris' H&E, using ×20 objective. The severity of insulitis was graded as a function of the mononuclear cell infiltration of the pancreatic islets: 0 = no infiltrate; 1 = peri-ductal infiltrate; 2 = periislet infiltrate; 3 = intra-islet infiltrate; 4 = intra-islet infiltrate associated with β-cell destruction, in accord with previous reports [30] . Thirty random islets were examined in each pancreas section, and the mean score was calculated by dividing the total score by the number of islets examined. These quantifications were performed double blind.
Detection of proliferation and apoptosis
To determine β-cell proliferation, animals were treated with intra-peritoneal BrdU (100 mg/kg body weight) 6 h before sacrifice. Pancreas samples were snap-frozen, embedded in optimal cutting temperature (Sakura Finetek, Zoeterwoude, The Netherlands), and cryostat 10-μm sections were generated and fixed in 4% methanol-free formaldehyde. Proliferation was assessed by double immunostaining using monoclonal mouse antibromodeoxyuridine (Dako Cytomation, Denmark) and polyclonal guinea pig anti-insulin (Sigma-Aldrich, St. Louis, MO, USA) antibodies. Sections were incubated for 30 min with 0.1% Triton-X100 (v/v) in phosphate-buffered saline (PBS) for tissue permeabilization and washed twice with PBS. Sections were then treated with HCl (2 N) in PBS for 30 min, neutralized with borax/borate buffer (0.1 M, pH 8.9) for 30 min, washed and incubated overnight at 4°C with anti-bromodeoxyuridine and anti-insulin antibodies. Stained sections were revealed using anti-mouse Immunoglobulin G (IgG) antibody (alexa-546 conjugated) and anti-guinea pig IgG (alexa-488 conjugated) antibodies (Molecular Probes Inc., Eugene, OR, USA). To determine the proliferating fraction, insulin-positive/BrdU-positive cell number and islet areas were quantified in a total of 50 islets per condition, using a confocal scanning microscope (Leica Microsystems, Wetzlar, Germany). Results were expressed as number of Insulin+/BrdU+ cells/mm 2 of islet. β-cell apoptosis was determined using the DeadEnd Fluorimetric TUNEL System (Promega, Madison, WI, USA) according to the manufacturer's instructions, simultaneously with insulin immunostaining. Quantification was as above, and the results were expressed as number of Insulin+/TUNEL+ cells/mm 2 of islet.
Neogenesis evaluation
Neogenesis was assessed with the same slides previously used to quantify β-cell mass histomorphometry. To this end, we counted insulin-positive cell clusters (i.e. groups of less than five β-cells, in the proximity of pancreatic ducts) in two pancreas sections per animal, using the ×20 objective. Results were expressed as number of Insulin + clusters/100 μm2. This method has been previously used and validated by other authors [31] [32] [33] ; however, it is only considered an indirect marker. Thus, we performed quantitative real-time polymerase chain reaction (PCR) for three different markers of β-cell neogenesis and functional maintenance: pdx-1, ngn3 and nkx2.2.
RNA isolation and real-time PCR
We isolated total RNA from frozen pancreatic samples conserved in an RNase inhibitor cocktail at the time of sacrifice, using the High Pure RNA Tissue Kit (Roche, Mannheim, Germany). Reverse transcription was performed with the Transcriptor First Strand cDNA Synthesis Kit (Roche, Mannheim, Germany) using 1 μg of RNA in 20 μL of reaction volume. The cDNA was diluted into 200 μL of sterile water for later use in real-time PCR. Three primer pairs were used to amplify the target genes: rPDX1-F, 5′-TCATCTCCCTTTCCCGTGGAT-3′; rPDX1-R, 5′-AGGCTGTACGGGTCCTCTTAT-3′; rNGN3-F, 5′-GAGTG GGTGGGCGTACTCTA-3′; rNGN3-R, 5′-TTGGAACTGAG CACTTCGTG-3′; rNKX2.2.-F, 5′-GGGGTTTTCAGTCAAGG ACA-3′; rNKX2.2.-R, 5′-AGTCCGTGCAGGGAGTATTG-3′. β-Actin mRNA expression was measured as an internal reference with the primers rBACT-F, 5′-CACCCGCGAG TACAACCTTC-3′; rBACT-R, 5′-CCCATACCCACCATCACA CC-3′. Real-time PCR was carried out in 10 μL reactions containing 5 μL of SensiFAST ™ SYBR No-ROX Kit (Bioline, London, UK), 0.5 μL forward primer, 0.5 μL reverse primer, 3 μL DEPC H2O and 1 μL cDNA template. Following the initial denaturalization at 95°C for 3 min, 40 cycles of amplification were performed with the following conditions: denature at 95°C for 15 s, annealing at 60°C for 20 s and extension at 72°C for 20 s. The threshold cycles of each mRNA species were determined in triplicate with the use of a LightCycler 1.5 (Roche, Mannheim, Germany). The mRNA levels of the target genes were expressed as relative folds over those of rBACT that was used as the internal reference.
Hormone level determination
At the time of sacrifice, blood was collected by heart puncture into gelose-containing tubes (BD Vacutainer, BecktonDickinson; Plymouth, UK); serum was separated by centrifugation at 5000 rpm for 5 min at 4°C, transferred to cryotubes and immediately frozen at À80°C until processed. Anterior pituitary hormone levels were detected by multiplex immunoassay (Millipore Corp., Billerica, MA, USA), whilst insulin-like growth factor 1 (IGF-I) levels were measured using a commercially available ELISA kit (Mediagnost, Reutlingen, Germany), according to the manufacturer's instructions in both cases.
Statistical analyses
Results are presented as means + Ghrelin treatment does not alter glucose homeostasis or disrupt insulin secretion in response to glucose overload
The AUC was plotted and calculated for blood glucose during IPGTT at weeks 7, 9 and 10 ( Figure 2A-D) . Thymectomized and ghrelin-treated animals presented similar values in all experimental points. Intact BB animals receiving vehicle showed an increasing trend in the AUC values reaching statistical significance at week 10, in which the morphology of the blood glucose curve for IPGTT indicates glucose intolerance. Insulin response at 15 min after glucose intraperitoneal administration is also similar between thymectomized and ghrelin-treated animals in every time point. Intact animals receiving vehicle also presented normal insulin responses on weeks 7 and 9, but on week 10, their insulin response was blunted, consistent with the glucose curve observed ( Figure 2E -G). To verify that the increased AUC was not due to altered insulin sensitivity, we performed insulin tolerance tests in both groups of intact animals, and the curves were similar at every experimental point ( Figure 2H-J) . Hence, the increased AUC displayed by the vehiclereceiving group is solely explained by a reduced insulin secretion in response to glucose.
Reduction of diabetes incidence in the ghrelin-receiving group by the end of the study A total of 36 vehicle-receiving animals and 32 ghrelin-treated animals were used for the survival analysis. Diabetes onset was registered and plotted as an 'event' in the survival curve ( Figure 3 ). All animals that had not presented diabetes onset by the age of 75 days were subsequently sacrificed. The proportion of healthy animals in the vehicle group (i.e. diabetesfree) by day 75 was 11.11% versus the 68.75% in the ghrelintreated group. This results in a cumulative incidence for diabetes at day 75 of 88.89% in the vehicle group and 31.25% in ghrelin-treated animals. The comparison of the curves by the log-rank (Mantel-Cox) test showed a significant difference between groups (p < 0.0001).
Ghrelin maintains functional β-cell mass during insulitis development
So far, our data indicates that ghrelin treatment in our model does not change weight or impair glucose metabolism, and its chronic administration from early stages of prediabetes reduces the animals' probability of diabetes onset by 10 weeks of age. To understand if β-cell mass was preserved with ghrelin treatment, we analysed three parameters β-cell mass, total islet area/total pancreatic area and total number of islets/pancreatic area. At week 10, intact BB rats experienced a profound decrease in all three parameters that was partially reversed by ghrelin treatment (Figure 4A-D) .
Effects of ghrelin on the autoimmune infiltrate in the BB rat
Intact BB rats suffer an autoimmune infiltrate on pancreatic islets that progresses from week 5 to a total destruction of the islets. To test the effects of ghrelin on infiltration levels, H&E-stained sections from all groups were evaluated ( Figure 5A ). BB intact animals receiving vehicle suffered a severe islet infiltration, whilst ghrelin treatment significantly reduced infiltration severity ( Figure 5B ).
Ghrelin increases β-cell proliferation, but does not prevent apoptosis β-cell proliferation and apoptosis were evaluated in pancreatic tissue sections at all time points. BB vehicleinjected animals showed a time-dependent decrease in β-cell proliferation as quantified by BrdU+/insulin + douuble stained cells, but ghrelin-treated animals showed a stable β-cell proliferation rate ( Figure 6A ). With respect to β-cell apoptosis, no differences were observed between experimental groups ( Figure 6B ). Graphs showing the morphometric characterization of pancreata from all experimental groups at different time points. A: β-cell mass was determined in pancreatic sections from thymectomized (hatched bars), intact vehicle (white bars) and intact ghrelin-treated (black bars) BB rats at 7, 9 and 10 weeks of age, (n = 5). β-cell mass is presented in the bar graph as means ± SEM in milligrams. B: Total islet area/total pancreatic area at 7, 9 and 10 weeks of age as measured on two pancreatic sections of thymectomized (hatched bars), intact vehicle (white bars) and intact ghrelin-treated (black bars) BB rats, (n = 5). Values are presented as means ± SEM of area (μm 2 ). C: Number of islets/pancreatic area on weeks 7, 9 and 10 as measured on two pancreatic sections of thymectomized (hatched bars), intact vehicle (white bars) and intact ghrelin-treated (black bars) BB rats, (n = 5). Values are presented as means ± SEM of islet number/area (μm Islet neogenesis during insulitis on the ghrelin-treated BB rat β-cell neogenesis has not been previously characterized in BB rats. An indirect marker of neogenesis is the presence of β-cell clusters (i.e. groups of less than five β-cells, in the proximity of pancreatic ducts). We quantified the number of clusters in all experimental groups at each time point of the experiment. Vehicle-treated animals showed a reduction in cluster numbers between 7 and 10 weeks of age. In contrast, the ghrelin-treated group maintained a similar pattern to our control animals ( Figure 7 ).
In accord with the histological findings, we also observed significantly higher levels of Pdx1 mRNA in ghrelin-treated animals (p < 0.001), together with increased Nkx2.2 expression, which did not reach statistical significance (p = 0.227), whilst no differences in Ngn3 expression was observed (Figure 8 ). 
Effects of ghrelin treatment on hormonal profile
Ghrelin stimulates secretion of many pituitary hormones, and some of these may serve as trophic factors for the β-cell; thus, we determined the anterior pituitary profile on control and treated rats on the day of sacrifice. The results are summarized on Table 1 . We found that ghrelintreated animals had significantly higher GH plasma levels than controls (p < 0.01). Because GH exerts more than 80% of its effects through the induction of IGF-I secretion, we quantified the IGF-I levels at sacrifice at different time points finding no differences in its levels between groups.
Discussion
Our data show for the first time the beneficial effects of ghrelin treatment during insulitis in an in vivo model of autoimmune diabetes. In our hands, ghrelin administration partially prevents β-cell mass loss, decreases islet infiltration and delays diabetes onset in an autoimmune model. Ghrelin did not induce increased food intake or weight gain, in accord with other authors using the same daily dose over an extended period of time [34] . As shown in Figure 1 , in the last week of the experiment, BB rats not receiving ghrelin slowed down their weight gain, whilst ghrelin-treated animals continued their normal weight gain as compared with thymectomized controls. This halt in weight gain experienced by the vehicle-receiving group may well be the clinical manifestation of incipient diabetes, as reflected by their impaired glucose tolerance and their decreased ability to secrete insulin in response to the glucose overload. This impaired increase in weight could then be the first manifestation of a latter weight loss, as a cardinal symptom of diabetes onset. As noted, ghrelin treatment did not impair glucose homeostasis. Groups that found a negative effect of ghrelin administration on glucose homeostasis used either higher doses and/or administered ghrelin in a continuous or repeated manner [35] [36] [37] . Although it could be argued that ghrelin's half-life is too short, isotopic studies of biodistribution demonstrate the uptake by the rat pancreas of exogenously administered ghrelin where it remains present for at least 4 h after administration [38] .
The primary aim of our study was to analyse the effects of ghrelin on protecting β-cell homeostasis during a continuous autoimmune aggression in vivo. This model simulates human T1D. BB rats are a non-obese model of spontaneous autoimmune diabetes that develops an absolute insulin deficiency soon after diabetes onset. Diabetes onset presents acutely, between 60 and 120 postnatal days, the median being 96 days [22] . In our colony, however, we observe an earlier presentation of the disease, and we therefore chose to sacrifice the animals at 10 weeks in order to target the prediabetic state. Ghrelin treatment prevented diabetes onset at 75 days of age in 68.75% of treated animals. In contrast, only 11.11% of vehicle-receiving rats where free of clinical disease at the same time point. Further investigation to determine ghrelin's effect on diabetes onset in these animals is warranted.
These functional findings correlated with a preserved β-cell mass. In accord with previous reports, thymectomized BB rats present a time-dependent increase in β-cell mass as do normal Wistar rats [29] . Vehicle-injected intact BB rats do not experience this time-dependent increase, and by week 10, they show a drastic decrease, consistent with their lower insulin response to glucose and glucose intolerance. Ghrelin treatment prevents this loss and maintains stable levels of β-cell mass throughout the experiment.
Our results indicate that ghrelin may act through different mechanisms to delay diabetes onset in this model. BB rats develop diabetes by a monolymphocytic infiltration of islets and subsequently, a more evident infiltration formed [23, 24] . Infiltrating cells secrete pro-inflammatory cytokines that can be detected in pancreatic tissue from the first stages of lymphocytic infiltration [25, 26] . These cytokines have been implicated in the pathophysiology of T1D [39] , and ghrelin immunomodulatory effects include inhibition of human lymphocyte and monocyte pro-inflammatory cytokine production [19] [20] [21] . We found that ghrelin treatment ameliorates islet infiltration, which is in accord with other authors' data on different models of pancreatic inflammation [10, 11, 34] , as well as data with obestatin [18] . Thus, this could be one of the mechanisms by which ghrelin maintains β-cell mass.
Cytokines trigger β-cell apoptosis by at least two wellknown mechanisms: on one hand, they induce an increase in nitric oxide (NO) production [40] , involved in β-cell dysfunction and death [41] , and on the other hand, cytokines directly activate proapoptotic signalling pathways such as NFkB [42] . Although ghrelin has been reported to interfere with both mechanisms [9, 11] , it did not prevent β-cell apoptosis in our model.
Islet β-cell regenerative response is crucial in maintaining glucose homeostasis when islet integrity is adversely affected. In substrate oversupply, and in 60% pancreatectomy models, an increase in β-cell proliferation has been found to be able to restore a normal plasma glucose level [43, 44] . As our group has previously shown, BB rats experience a progressive decline in β-cell proliferation rates as insulitis develops, and it is pro-inflammatory cytokines that drive this decrease in β-cell proliferation, both in cultured cell lines and islets [13, 29, 45] . This decrease in β-cell proliferation rates is partially mediated by an inhibition of mitogen-activated protein kinase (MAPK)-belonging extracellular signal-regulated kinases (ERK) 1/2 pathway. Because ghrelin activates ERK 1/2 pathway even in the presence of cytokines [13] , this is a plausible explanation as to how ghrelin restores β-cell proliferation rates at week 10 that are otherwise practically absent in animals receiving vehicle.
β-cell self-replication has been proposed as the main mechanism for β-cell mass recovery following islet injury [46] ; however, neogenesis could also play a key role in the regenerative response [47] . Ghrelin regulates cell differentiation in various tissues [48, 49] , and its higher level in the fetal pancreas during gestation suggests a role in endocrine pancreas development. Ghrelin upregulates expression of Pdx-1, a transcription factor that plays a central role in pancreatic endocrine lineage development and β-cell function and survival [15, 16, 50, 51] .
In accordance, we have also found an increase in Pdx-1 mRNA in the pancreata of our ghrelin-treated animals, which could explain the sustained ability to regenerate, proliferate and properly function observed in ghrelintreated rats β-cells. Moreover, we show for the first time that the decreased capability for β-cell neogenesis plays a role in the loss of β-cell mass in this diabetes model, as has been previously described in humans [51] , and ghrelin restores this phenomenon.
In conclusion, our work describes for the first time that ghrelin treatment during the early stages of insulitis delays diabetes clinical onset in an animal model of spontaneous autoimmune diabetes. Ghrelin preserves functional β-cell mass, inducing β-cell neogenesis, β-cell proliferation and modulating the autoimmune infiltrate.
